INTERNATIONAL PATENT: LEIBNIZ-INSTITUT FUR IMMUNTHERAPIE (LIT), THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES FILES APPLICATION FOR "USE OF LMO4 TO BOLSTER STEMNESS AND ANTITUMOR EFFICACY OF T-CELLS"

GENEVA, July 14 -- LEIBNIZ-INSTITUT FUR IMMUNTHERAPIE (LIT) (Franz-Josef-StrauB-Allee 1193053 Regensburg), THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (National Institutes of Health / 6701 RockledgeDrive, Suite 700Bethesda, Maryland 7788) filed a patent application (PCT/EP2025/050005) for "USE OF LMO4 TO BOLSTER STEMNESS AND ANTITUMOR EFFICACY OF T-CELLS" on Jan 02, 2025. With publication no. WO/2025/146440, the details related to the patent application was published on Jul 10, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): GATTINON...